Antispasmodic Therapy for Abdominal Pain

Guideline Recommendations

The American Gastroenterological Association recommends antispasmodic agents (hyoscine, dicyclomine, and peppermint oil) as a therapeutic option for patients with abdominal pain. 1, 2, 3

Antispasmodics provide a statistically significant reduction in abdominal pain compared with placebo (Risk Ratio 0.74; 95 % CI 0.59‑0.93); however, the certainty of this evidence is very low due to risk of bias and publication concerns. 4, 1
Across multiple trials, antispasmodics achieve consistent improvement in overall gastrointestinal symptoms (Risk Ratio 0.67; 95 % CI 0.55‑0.80). 4, 1, 2

These agents reduce smooth‑muscle contraction and may attenuate visceral hypersensitivity, making them particularly useful for post‑prandial abdominal discomfort. 4, 1

Recommended for patients with irritable bowel syndrome who have predominant abdominal pain or cramping. 4, 1
May be considered for post‑prandial pain, although randomized controlled trial evidence for this specific indication is lacking. 1, 3

Common, mild adverse effects include dry mouth, dizziness, and blurred vision. 4, 1
No serious adverse events have been reported in the evaluated studies. 1, 2
Regular use should be avoided in patients whose symptoms are dominated by constipation, because anticholinergic activity can exacerbate constipation. 4, 1, 3

The overall certainty of evidence for antispasmodic therapy is low to very low, reflecting heterogeneity among 22 randomized trials (total ≈ 3,000 participants) in study design, dosing regimens, and outcome measures. 4, 1

Tricyclic antidepressants (TCAs) have demonstrated superior pain relief (Risk Ratio 0.76‑0.94 for abdominal pain) and rank highest for pain‑specific outcomes in network meta‑analyses. 5
Low‑dose amitriptyline (≈ 10 mg at bedtime) has shown efficacy for abdominal pain relief. 5
The analgesic benefit of TCAs is independent of their antidepressant effect and may require several weeks to manifest. 5
TCAs are associated with a higher rate of treatment discontinuation due to adverse effects (Risk Ratio 2.11; 95 % CI 1.35‑3.28). 5

In adults with IBS, therapeutic trials of antispasmodic agents are typically conducted for 4–12 weeks to evaluate efficacy. 6

The most frequently reported adverse effects of antispasmodics in IBS patients are dry mouth, dizziness, and blurred vision. 6
No serious adverse events have been reported in the evaluated IBS studies of antispasmodic therapy. 6

The overall certainty of the evidence supporting antispasmodic use for IBS is low to very low, reflecting heterogeneity across 22 randomized trials involving approximately 3,000 participants. 6

Antispasmodic agents produce a statistically significant reduction in abdominal pain compared with placebo (Risk Ratio = 0.74; 95 % CI 0.59–0.93). The modest upper confidence limit suggests limited clinical benefit. 6
They also achieve global symptom improvement (RR = 0.67; 95 % CI 0.55–0.80), indicating a broader benefit on overall IBS symptom burden. 6
The confidence in these effect estimates is limited by publication bias and risk of bias within individual trials. 6